Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Infection
Published in: Infection 3/2012

01-06-2012 | Case Report

First case of anti-ganglioside GM1-positive Guillain–Barré syndrome due to hepatitis E virus infection

Authors: I. Maurissen, A. Jeurissen, T. Strauven, D. Sprengers, B. De Schepper

Published in: Infection | Issue 3/2012

Login to get access

Abstract

A 51-year-old previously healthy woman presented with Guillain–Barré syndrome (GBS) and elevated liver enzymes. Further diagnostic investigations showed the presence of an acute hepatitis E infection associated with anti-ganglioside GM1 antibodies. After treatment with intravenous immunoglobulins, the patient made a rapid recovery. Here, we report the first case of GBS due to acute hepatitis E virus (HEV) infection associated with the presence of anti-ganglioside GM1 antibodies. We also review available literature on the association between acute HEV infection and GBS.
Literature
1.
Bihl F, Negro F. Hepatitis E virus: a zoönosis adapting to humans. J Antimicrob Chemother. 2010;65:817–21.PubMedCrossRef
2.
Dalton HR, Bendall R, Ijaz S, Banks M. Hepatitis E: an emerging infection in developed countries. Lancet Inf Dis. 2008;8:698–709.CrossRef
3.
Romano L, Paladini S, Tagliacarne C, Canuti M, Bianchi S, Zanetti AR. Hepatitis E in Italy: a long-term prospective study. J Hepatol. 2011;54:34–40.PubMedCrossRef
4.
Kamar N, Izopet J, Cintas P, Garrouste C, Uro-Coste E, Cointault O, Rostaing L. Hepatitis E virus-induced neurological symptoms in a kidney-transplant patient with chronic hepatitis. Am J Transplant. 2010;10:1321–4.PubMedCrossRef
5.
Kamani P, Baijal R, Amarapurkar D, Gupte P, Patel N, Kumar P, Agal S. Guillain–Barré syndrome associated with acute hepatitis E. Indian J Gastroenterol. 2005;24:216.PubMed
6.
Sood A, Vandana M, Sood N. Guillain–Barré syndrome with acute hepatitis E. Am J Gastroenterol. 2000;95:3667–8.PubMed
7.
Loly JP, Rikir E, Seivert M, Legros E, Defrance P, Belaiche J, Moonen G, Delwaide J. Guillain–Barré syndrome following hepatitis E. World J Gastroenterol. 2009;15:1645–7.PubMedCrossRef
8.
Cronin S, McNicholas R, Kavanagh E, Reid V, O’Rourke K. Anti-glycolipid GM2-positive Guillain–Barré syndrome due to hepatitis E infection. Ir J Med Sci. 2011;180:255–7.PubMedCrossRef
9.
Kumar R, Bhoi S, Kumar M, Sharma B, Singh B, Gupta B. Guillain–Barré syndrome and acute hepatitis E: a rare association. J Indian Acad Clin Med. 2002;3:389–91.
10.
11.
Purcell RH, Emerson SU. Hepatitis E: an emerging awareness of an old disease. J Hepatol. 2008;48:494–503.PubMedCrossRef
12.
Teshale EH, Hu DJ, Holmberg SD. The two faces of hepatitis E virus. Clin Inf Dis. 2010;51:328–34.CrossRef
13.
Andriesse GI, Donmez M, Vissers J, Van Wijngaarden P. Acute hepatitis, but not A, B, or C: consider E. Ned Tijdschr Geneeskd. 2010;154:A1865.PubMed
14.
15.
Jacobs BC. Guillain Barré-Syndrome. Ned Tijdsch Klin Chem Labgeneesk. 2001;32:184–5.
16.
Kaida K, Kusunoki S. Antibodies to gangliosides and ganglioside complexes in Guillain–Barré syndrome and Fisher syndrome: mini-review. J Neuroimmunol. 2010;223:5–12.PubMedCrossRef
17.
Ang CW, Dijkstra JR, De Klerk MA, Endtz HP, Van Doorn PA, Jacobs BC, Jeurissen SH, Wagenaar JA. Host factors determine anti-GM1 response following oral challenge of chickens with Guillain–Barré syndrome derived Campylobacter jejuni strain GB11. PLOS One. 2010;5:e9820.PubMedCrossRef
18.
Yuki N, Yamada M, Koga M, Odaka M, Susuki K, Tagawa Y, Ueda S, Kasama T, Ohnishi A, Hayashi S, Takahashi H, Kamijo M, Hirata K. Animal model of axonal Guillain–Barré syndrome induced by sensitization with GM1 ganglioside. Ann Neurol. 2001;49:712–20.PubMedCrossRef
Metadata
Title
First case of anti-ganglioside GM1-positive Guillain–Barré syndrome due to hepatitis E virus infection
Authors
I. Maurissen
A. Jeurissen
T. Strauven
D. Sprengers
B. De Schepper
Publication date
01-06-2012
Publisher
Springer-Verlag
Published in
Infection / Issue 3/2012
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-011-0185-6

Other articles of this Issue 3/2012

Infection 3/2012 Go to the issue

Clinical and Epidemiological Study

Mortality after bloodstream infections in allogeneic haematopoietic stem cell transplant (HSCT) recipients

Erratum

Erratum to: Respiratory viruses in patients and employees in an intensive care unit

Correspondence

Hepatitis B virus surface antigen seroconversion after pegylated interferon-alpha treatment in an HIV-infected individual with chronic hepatitis B

Case Report

Rat bite fever as a presenting illness in a patient with AIDS

Correspondence

A severe case of paediatric group A streptococcal osteomyelitis in varicella

Review

Resistance surveillance studies: a multifaceted problem—the fluoroquinolone example
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits